Related Experiment Video
Updated: Jun 3, 2026
07:29
Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Additional applications of corneal cross linking.
Vassilios Kozobolis1, Georgios Labiris, Maria Gkika
1Eye Institute of Thrace (EIT), Democritus University, Alexandroupolis, Greece.
The Open Ophthalmology Journal
|March 31, 2011
Summary
Corneal collagen cross-linking (CxL) is effective beyond keratoconus. This review highlights CxL
Area of Science:
- Ophthalmology
- Corneal Surgery
- Biomaterials Science
Background:
- Corneal collagen cross-linking (CxL) is a standard treatment for keratoconus.
- Emerging evidence suggests CxL's efficacy in other corneal conditions.
- A comprehensive review of these additional applications is warranted.
Purpose of the Study:
- To review contemporary literature on the expanded applications of corneal collagen cross-linking (CxL).
- To evaluate the therapeutic benefits of CxL in various corneal pathologies beyond keratoconus.
Main Methods:
- Systematic literature search of recent studies on CxL applications.
- Analysis of clinical outcomes for CxL in iatrogenic ectasias, pellucid marginal degeneration, infectious keratitis, bullous keratopathy, and ulcerative keratitis.
Main Results:
- CxL demonstrates significant benefits in managing iatrogenic ectasias.
- Studies show positive outcomes for CxL in pellucid marginal degeneration.
- CxL is effective as both a primary and adjuvant therapy for infectious and ulcerative keratitis, and bullous keratopathy.
Conclusions:
- Corneal collagen cross-linking (CxL) offers therapeutic potential for a range of corneal conditions.
- CxL can be considered a primary or adjunctive treatment for iatrogenic ectasias, pellucid marginal degeneration, infectious keratitis, bullous keratopathy, and ulcerative keratitis.
- Further research into CxL's role in these additional applications is supported.
